Corrigendum to "Lipid-liquid crystals for 2 months controlled risperidone release : In-vitro evaluation and pharmacokinetics in rabbits" [Int. J. Pharm. 618 (2022) 121649
| Errataetall: |
ErratumFor: Int J Pharm. 2022 Apr 25;618:121649. - PMID 35278600 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:635 |
|---|---|
| Enthalten in: |
International journal of pharmaceutics - 635(2023) vom: 25. März, Seite 122673 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shiadeh, Seyedeh Nesa Rezaeian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 17.03.2023 published: Print-Electronic ErratumFor: Int J Pharm. 2022 Apr 25;618:121649. - PMID 35278600 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ijpharm.2023.122673 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352492473 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352492473 | ||
| 003 | DE-627 | ||
| 005 | 20231226053840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2023.122673 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352492473 | ||
| 035 | |a (NLM)36739233 | ||
| 035 | |a (PII)S0378-5173(23)00093-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shiadeh, Seyedeh Nesa Rezaeian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corrigendum to "Lipid-liquid crystals for 2 months controlled risperidone release |b In-vitro evaluation and pharmacokinetics in rabbits" [Int. J. Pharm. 618 (2022) 121649 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumFor: Int J Pharm. 2022 Apr 25;618:121649. - PMID 35278600 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Khodaverdi, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Faal Maleki, Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Eisvand, Farhad |e verfasserin |4 aut | |
| 700 | 1 | |a Boujaran, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Zarei, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Vosooghi, Ramin |e verfasserin |4 aut | |
| 700 | 1 | |a Hadizadeh, Farzin |e verfasserin |4 aut | |
| 700 | 1 | |a Kamali, Hossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pharmaceutics |d 1992 |g 635(2023) vom: 25. März, Seite 122673 |w (DE-627)NLM07779785X |x 1873-3476 |7 nnns |
| 773 | 1 | 8 | |g volume:635 |g year:2023 |g day:25 |g month:03 |g pages:122673 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijpharm.2023.122673 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 635 |j 2023 |b 25 |c 03 |h 122673 | ||